PMC5096402_01
A, Serum concentration of lipids at the time of CESD diagnosis until medical optimization of the patient's dyslipidemia. (1) baseline (2) cholestyramine/low-fat diet (3) cornstarch/low-fat diet (4) cholestyramine/low-fat diet (5) atorvastatin 20 mg (6) atorvastatin 40 mg (7) rosuvastatin 40 mg (8) atorvastatin 40 mg + ezetimibe 10 mg (9) atorvastatin 40 mg + ezetimibe 10 mg. B, Serum concentration of liver aminotransferases and alkaline phosphatase at the time of CESD diagnosis until medical optimization of the patient's dyslipidemia. (1) baseline (2) cholestyramine (3) cornstarch/low-fat diet (4) cholestyra-mine/low-fat diet (5) atorvastatin 40 mg (6) rosuvastatin 40 mg (7) atorvastatin 40 mg + ezetimibe 10 mg (8) atorvastatin 40 mg + ezetimibe 10 mg.
nihms-825545-f0001.jpg
PMC5096402_01_nihms-825545-f0001.jpg
F1
A decision was made to start the patient on cholestyramine with a low-fat diet which showed some improvement in her lipid profile as indicated in Figure 1A. The patient's lipid profile (Figure 1A) and liver function tests (Figure 1B) are indicated graphically at the time of diagnosis and throughout the evolution of her treatment regimen.